 180 Life Sciences Corp NASDAQ: ATNF received a written response from the U.K.s regulatory agency and U.S. FDA related to questions submitted in a Type C meeting request for anti-TNF treatment, adalimumab, to treat early-stage Dupuytrens disease. Dupuytrens disease. 